Public domain

Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:15am

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.

Key Points: 
  • However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.
  • The report provides a comprehensive analysis of the global antiviral drugs market.

Insights into the Worldwide Antiviral Drugs Industry to 2024 - Potential Impact of COVID-19 - ResearchAndMarkets.com

Friday, May 22, 2020 - 2:55pm

The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.

Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Wednesday, May 13, 2020 - 10:08pm

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020

Friday, May 8, 2020 - 6:30pm

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Amneal Launches Generic Butrans® Following ANDA Approval by FDA

Thursday, April 16, 2020 - 12:00pm

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr.
  • In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose.
  • Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
  • Amneal Co-Chief Executive Officers Chirag Patel and Chintu Patel said, Expanding our portfolio of complex generic drug products and providing patients access to affordable generic medicines will continue to set Amneal apart.

FPP and Inventia Sign Licensing and Supply Agreement

Friday, April 3, 2020 - 8:00pm

(FPP), a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals, and Inventia Healthcare Limited (Inventia), a company involved in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of an ANDA developed by Inventia recently approved by the FDA and scheduled to launch this Summer.

Key Points: 
  • (FPP), a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals, and Inventia Healthcare Limited (Inventia), a company involved in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of an ANDA developed by Inventia recently approved by the FDA and scheduled to launch this Summer.
  • The ANDA product will be Sold and Distributed by FPP in the FPP Label within the US.
  • "We are excited to work with Inventia on this opportunity and look forward to launching the product ", said Larry J. Lapila, President of FPP.
  • "Inventia is excited to add a new partner to the current portfolio of ANDAs and we are working together with FPP towards a successful launch of the product", said Ankur J. Shah, Whole-time Director of Inventia.

Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026

Wednesday, April 1, 2020 - 6:05pm

NEW YORK, April 1, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

Key Points: 
  • NEW YORK, April 1, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality.
  • The ease in developing the drug and the high adoption rate by the patients contribute largely to the established markets of cancer generics.
  • Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive.
  • The research report "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe.

Global Generic Drugs Market Analysis to 2026 - Vendors Covered Include Cipla, Novartis, Valeant & Baxter International Among Others - ResearchAndMarkets.com

Friday, March 27, 2020 - 4:46pm

The "Global Generic Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Generic Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Generic Drugs market is expected to reach $738.56 billion by 2026 growing at a CAGR of 12.6% from 2018 to 2026.
  • Generic drugs are drugs with the chemical makeup of a drug equivalent to an existing branded drug.
  • These drugs are cheaper and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application.

Global Cancer Generics Market (2018 to 2026) - Reimbursement Policies & the Coverage Strategies by Country - ResearchAndMarkets.com

Wednesday, March 18, 2020 - 10:28am

The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • It is a result of the extensive study conducted by analyzing the global companies for cancer generics.
  • Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive.
  • The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

A US-Based Generic Drugs Market Client Achieved Savings of Over $8.8 Million with Market Intelligence Engagement | RFP for Similar Engagement for Your Business

Tuesday, March 17, 2020 - 1:17pm

Also, gather detailed insights into the approach undertaken by the experts at Infiniti Research to help the generic drugs market client achieve savings of over $8.8 million in a year.

Key Points: 
  • Also, gather detailed insights into the approach undertaken by the experts at Infiniti Research to help the generic drugs market client achieve savings of over $8.8 million in a year.
  • However, evolving governmental regulations and rising generic drug prices are expected to hamper the generic drugs market development.
  • As such, generic drugs manufacturers will need to foresee changing market dynamics and look for other markets to sustain growth.
  • Besides, the rising concerns about the safety and efficacy of extended-release generic drugs made it difficult for the generic drugs market client to promote their products.